firstwordpharmaMarch 03, 2019
Tag: Spectrum Pharmaceuticals , Completion , Marketed Portfolio
Spectrum Pharmaceuticals, Inc. (NASDAQ-GS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today completed the sale of its portfolio of seven FDA-approved hematology/oncology products to Acrotech Biopharma L.L.C., a step-down subsidiary of Aurobindo Pharma Limited, India.
"The completion of this sale marks a significant pivot point in Spectrum's history as we focus our efforts on our two promising late stage assets, ROLONTIS® and poziotinib," stated Joe Turgeon, President and CEO of Spectrum Pharmaceuticals. "This transaction puts us in a strong capital position for the next chapter of our growth."
Under the terms of the agreement, Acrotech will make a $158.8 million up-front cash payment which represents the original payment of $160 million less certain purchase price adjustments for certain R&D activities. In addition, the company is eligible to receive up to $140 million in milestone payments. Spectrum has also reduced its staff by approximately 40 percent with the majority of impacted staff transitioning to Acrotech. Spectrum has retained a core group of commercial leadership talent to launch ROLONTIS® and poziotinib.
The seven products included in the sale are: FUSILEV® (levoleucovorin), FOLOTYN®(pralatrexate injection), ZEVALIN® (ibritumomab tiuxetan), MARQIBO® (vinCRIStine sulfate LIPOSOME injection), BELEODAQ® (belinostat) for injection, EVOMELA®(melphalan) for injection, and KHAPZORYTM (levoleucovorin).
Jefferies LLC acted as exclusive financial advisor to Spectrum. Paul Hastings LLP acted as exclusive legal counsel to Spectrum.
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: